Enhanced clopidogrel responsiveness in smokers: Smokers' paradox is dependent on cytochrome P450 CYP1A2 status

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 31, Issue 3, 2011, Pages 665-671

  Park, Kyung Woo ^a   Park, Jin Joo ^a   Jeon, Ki Hyun ^a   Kang, Si Hyuk ^a   Oh, Il Young ^a   Yang, Han Mo ^a   Cho, Hyun Jai ^a   Lee, Hae Young ^a   Kang, Hyun Jae ^a   Koo, Bon Kwon ^a   Oh, Byung Hee ^a   Park, Young Bae ^a   Kim, Hyo Soo ^a  

^a Seoul National University Hospital   (South Korea)

Author keywords

cigarette smoking; CYP1A2; genetic polymorphism; on treatment platelet reactivity; thienopyridines

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CALCIUM CHANNEL BLOCKING AGENT; CHOLESTEROL; CLOPIDOGREL; CREATININE; CYCLOOXYGENASE 2 INHIBITOR; CYTOCHROME P450 1A2; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MULTIDRUG RESISTANCE PROTEIN 1; NONSTEROID ANTIINFLAMMATORY AGENT; PROTON PUMP INHIBITOR; TRIACYLGLYCEROL;

ADULT; ANGIOCARDIOGRAPHY; ARTICLE; BLOOD CLOTTING PARAMETERS; BODY MASS; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG METABOLISM; DRUG RESPONSE; FEMALE; GENETIC ANALYSIS; GENETIC VARIABILITY; GENOTYPE; HEART INFARCTION; HEMOGLOBIN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; THROMBOCYTE FUNCTION; TRIACYLGLYCEROL BLOOD LEVEL;

AGED; CHI-SQUARE DISTRIBUTION; CROSS-SECTIONAL STUDIES; CYTOCHROME P-450 CYP1A2; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; LINEAR MODELS; LOGISTIC MODELS; MALE; MIDDLE AGED; ODDS RATIO; PHENOTYPE; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSPECTIVE STUDIES; RECEPTORS, PURINERGIC P2Y12; REPUBLIC OF KOREA; RISK ASSESSMENT; RISK FACTORS; SMOKING; TICLOPIDINE;

EID: 79952192512     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/ATVBAHA.110.217182     Document Type: Article

References (23)

1. Angiolillo D, Ferreiro J. Platelet adenosine diphosphate P2Y 12 receptor antagonism: benefits and limitations of current treatment strategies and future directions. Rev Esp Cardiol. 2010;63:60-76.
2. Kurihara A, Hagihara K, Kazui M, Ozeki T, Farid N, Ikeda T. In vitro metabolism of antiplatelet agent clopidogrel: cytochrome P450 isoforms responsible for two oxidation steps involved in the active metabolite formation. Drug Metab Rev. 2005;37:99.
3. Geisler T, Langer H, Wydymus M, Gohring K, Zurn C, Bigalke B, Stellos K, May AE, Gawaz M. Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation. Eur Heart J. 2006;27:2420-2425. (Pubitemid 44522148)
4. Gurbel PA, Bliden KP, Samara W, Yoho JA, Hayes K, Fissha MZ, Tantry US. Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST study. J Am Coll Cardiol. 2005;46:1827-1832. (Pubitemid 41579803)
5. Matetzky S, Shenkman B, Guetta V, Shechter M, Bienart R, Goldenberg I, Novikov I, Pres H, Savion N, Varon D, Hod H. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation. 2004;109:3171-3175.
6. Bliden KP, Dichiara J, Lawal L, Singla A, Antonino MJ, Baker BA, Bailey WL, Tantry US, Gurbel PA. The association of cigarette smoking with enhanced platelet inhibition by clopidogrel. J Am Coll Cardiol. 2008;52:531-533.
7. Price MJ, Nayak KR, Barker CM, Kandzari DE, Teirstein PS. Predictors of heightened platelet reactivity despite dual-antiplatelet therapy in patients undergoing percutaneous coronary intervention. Am J Cardiol. 2009;103:1339-1343.
8. Gremmel T, Steiner S, Seidinger D, Koppensteiner R, Panzer S, Kopp CW. Smoking promotes clopidogrel-mediated platelet inhibition in patients receiving dual antiplatelet therapy. Thromb Res. 2009;124: 588-591.
9. Saraff K, Steinhubl S, Hsu A, Topol E. Smoking influences the effectiveness of dual antiplatelet therapy on long-term outcomes following percutaneous coronary intervention (Abstract). J Am Coll Cardiol. 2006;47:36B.
10. Berger J, Bhatt D, Steinhubl S, Shao M, Steg P, Montalescot G, Hacke W, Fox K, Lincoff A, Topol E. Smoking, clopidogrel, and mortality in patients with established cardiovascular disease. Circulation. 2009;120:2337.
11. Sachse C, Brockmoller J, Bauer S, Roots I. Functional significance of a c->a polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. Br J Clin Pharmacol. 1999;47:445-449. (Pubitemid 29161279)
12. Ghotbi R, Christensen M, Roh H, Ingelman-Sundberg M, Aklillu E, Bertilsson L. Comparisons of CYP1A2 genetic polymorphisms, enzyme activity and the genotype-phenotype relationship in Swedes and Koreans. Eur J Clin Pharmacol. 2007;63:537-546. (Pubitemid 46684487)
13. Malinin A, Pokov A, Swaim L, Kotob M, Serebruany V. Validation of a VerifyNow-P2Y12 cartridge for monitoring platelet inhibition with clopidogrel. Methods Find Exp Clin Pharmacol. 2006;28:315-322. (Pubitemid 44047198)
14. Malinin A, Pokov A, Spergling M, Defranco A, Schwartz K, Schwartz D, Mahmud E, Atar D, Serebruany V. Monitoring platelet inhibition after clopidogrel with the VerifyNow-P2Y12(r) rapid analyzer: the Verify Thrombosis Risk Assessment (VERITAS) study. Thromb Res. 2007;119: 277-284. (Pubitemid 44918092)
15. Marin F, Gonzalez-Conejero R, Capranzano P, Bass TA, Roldan V, Angiolillo DJ. Pharmacogenetics in cardiovascular antithrombotic therapy. J Am Coll Cardiol. 2009;54:1041-1057.
16. Herbert JM, Savi P. P2Y12, a new platelet ADP receptor, target of clopidogrel. Semin Vasc Med. 2003;3:113-122.
17. Gurbel P, Bliden K, Hiatt B, O'Connor C. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation. 2003;107:2908.
18. Zhou S, Yang L, Zhou Z, Liu Y, Chan E. Insights into the substrate specificity, inhibitors, regulation, and polymorphisms and the clinical impact of human cytochrome P450 1A2. AAPS J. 2009;11:481-494.
19. Fuhr U, Rost KL. Simple and reliable CYP1A2 phenotyping by the paraxanthine/caffeine ratio in plasma and in saliva. Pharmacogenetics. 1994;4:109-116. (Pubitemid 24210928)
20. Eaton DL, Gallagher EP, Bammler TK, Kunze KL. Role of cytochrome P4501A2 in chemical carcinogenesis: implications for human variability in expression and enzyme activity. Pharmacogenetics. 1995;5:259-274.
21. Kalow W, Tang BK. Use of caffeine metabolite ratios to explore CYP1A2 and xanthine oxidase activities. Clin Pharmacol Ther. 1991;50: 508-519.
22. MacLeod S, Tang Y, Yokoi T, Kamataki T, Doublin S, Lawson B, Massengill J, Kadlubar F, Lang N. The role of recently discovered genetic polymorphism in the regulation of the human CYP1A2 gene. Proc Am Assoc Cancer Res. 1998;39:396.
23. Altayli E, Gunes S, Yilmaz AF, Goktas S, Bek Y. CYP1A2, CYP2D6, GSTM1, GSTP1, and GSTT1 gene polymorphisms in patients with bladder cancer in a Turkish population. Int Urol Nephrol. 2009;41:259-266.